



PRESS RELEASE NOVEMBER 17, 2015

## MOBERG PHARMA'S NOMINATION COMMITTEE APPOINTED

In accordance with the resolution of the Annual General Meeting on May 11, 2015, the Chairman of the Board has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company's three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 11.

Moberg Pharma's Nomination Committee ahead of the 2016 Annual General Meeting comprises:

- Mats Petterson, Chairman of the Board
- Per-Olof Edin, appointed by Östersjöstiftelsen
- Elisabet Jamal Bergström, appointed by Handelsbanken Fonder
- Anders Rodebjer, appointed by Wolco Invest

Per-Olof Edin has been appointed Chairman of the Nomination Committee. Together, the Nomination Committee represents 29.1 percent of the shares in Moberg Pharma as of September 30, 2015.

The Nomination Committee shall submit proposals for resolution by the 2016 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2016 Annual General Meeting will be held in Stockholm on May 18.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to [info@mobergpharma.se](mailto:info@mobergpharma.se) by 31 December 2015.

**For additional information, please contact:**

Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail: [peter.wolpert@mobergpharma.se](mailto:peter.wolpert@mobergpharma.se)

Anna Ljung, CFO, Phone: +46 (0)70 – 766 60 30, Email: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

**About this information**

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 am (CET) on November 17, 2015.

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal<sup>®</sup>, Kerasal Nail<sup>®</sup>, Balmex<sup>®</sup>, Domeboro<sup>®</sup>, Jointflex<sup>®</sup>, Vanquish<sup>®</sup>, and Fergon<sup>®</sup>. Kerasal Nail<sup>®</sup> (Emtrix<sup>®</sup> or Nalox<sup>™</sup> in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).